There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Irhythm Technologies (IRTC – Research Report), AbbVie (ABBV – Research Report) and CymaBay Therapeutics (CBAY – Research Report) with bullish sentiments.
Irhythm Technologies (IRTC)
In a report released today, Nathan Treybeck from Wells Fargo maintained a Buy rating on Irhythm Technologies, with a price target of $125.00. The company’s shares closed last Tuesday at $101.34.
According to TipRanks.com, Treybeck is ranked #3578 out of 8665 analysts.
Currently, the analyst consensus on Irhythm Technologies is a Strong Buy with an average price target of $123.60, representing a 17.1% upside. In a report issued on December 21, Canaccord Genuity also maintained a Buy rating on the stock with a $121.00 price target.
See today’s best-performing stocks on TipRanks >>
AbbVie (ABBV)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on AbbVie today and set a price target of $180.00. The company’s shares closed last Tuesday at $159.82.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
Currently, the analyst consensus on AbbVie is a Moderate Buy with an average price target of $170.33.
CymaBay Therapeutics (CBAY)
In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on CymaBay Therapeutics, with a price target of $36.00. The company’s shares closed last Tuesday at $23.71, close to its 52-week high of $25.33.
According to TipRanks.com, PhD is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CymaBay Therapeutics with a $28.67 average price target, implying a 22.3% upside from current levels. In a report issued on December 22, H.C. Wainwright also maintained a Buy rating on the stock with a $28.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IRTC:
- iRhythm Technologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- iRhythm price target raised by $15 at Truist, here’s why
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- iRhythm just upgraded at Citi, here’s why
- Citi gets more bullish on iRhythm, upgrades shares
